Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.18, Zacks reports. Sonoma Pharmaceuticals had a negative return on equity of 50.00% and a negative net margin of 23.87%.The company had revenue of $5.60 million during the quarter, compared to the consensus estimate of $4.26 million.
Sonoma Pharmaceuticals Stock Performance
Shares of NASDAQ:SNOA traded down $0.12 during midday trading on Thursday, hitting $3.64. 22,048 shares of the stock were exchanged, compared to its average volume of 1,178,740. The stock has a market capitalization of $5.98 million, a price-to-earnings ratio of -1.48 and a beta of 1.45. The business’s 50-day moving average price is $4.14 and its 200 day moving average price is $3.69. Sonoma Pharmaceuticals has a 12 month low of $1.75 and a 12 month high of $6.92.
Wall Street Analyst Weigh In
A number of research analysts recently commented on SNOA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sonoma Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen raised Sonoma Pharmaceuticals to a “hold” rating in a research note on Friday, October 3rd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
Further Reading
- Five stocks we like better than Sonoma Pharmaceuticals
- The Significance of Brokerage Rankings in Stock Selection
- The Metals Market Is Heating Up—4 Stocks Poised to Shine
- 3 Healthcare Dividend Stocks to Buy
- Tempus AI: Volatility Equates to Opportunity in AI Leader
- Compound Interest and Why It Matters When Investing
- Follow the Money: 3 Stocks With High Institutional Ownership
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
